HC Wainwright & Co. Initiates Coverage On Immix Biopharma with Buy Rating, Announces Price Target of $7

Benzinga · 07/01 10:10
HC Wainwright & Co. analyst Robert Burns initiates coverage on Immix Biopharma (NASDAQ:IMMX) with a Buy rating and announces Price Target of $7.